TTNP Titan Pharmaceuticals: Company Short-Term Debt

Corporate emblem and logo of Titan Pharmaceuticals, Inc. (TTNP)

Titan Pharmaceuticals (TTNP) develops innovative implants to combat opioid addiction, utilizing its proprietary ProNeura platform to block competitors. The business relies on licensing unique drug delivery systems to industry behemoths, ensuring high scalability. The company is currently restructuring its distribution, and the indicator stands at 0.00. This chart illustrates the price action of the asset.

Titan Pharma (TTNP) - Company Short-Term Loans and Borrowings from 07/04/2022 to 10/18/2025

Summary analytical data breakdowns for Titan Pharmaceuticals Inc. (TTNP)

- stock price and consensus target price:
Stock Price Titan Pharma|TTNP - Consensus Target
- company stock capitalization data:
Market Value Titan Pharmaceuticals, Inc.|TTNP - Total Enterprise Value
- shareholders' equity book value data:
Accounting Value per Share Titan Pharmaceuticals|TTNP - Accounting Value of Company|Market Capitalization to Book Value Ratio titanpharm.com|TTNP - Total Asset Value of Company
- debt and liquidity details:
Total Debt to Capital Titan Pharmaceuticals|TTNP - Long-Term Debt to Capital|Short-Term Debt to Equity Titan Pharma|TTNP - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Titan Pharmaceuticals, Inc.|TTNP - Company Long-Term Liabilities|Company Current Liabilities Titan Pharmaceuticals|Quick Ratio titanpharm.com
- earnings and valuation multiples indicators:
TTNP - Net Financial Result
General company analysis:TTNP - titanpharm.com
Manufactured products of Titan Pharma

Short-term liabilities measure current credit load and liquidity, determining a business's ability to service loans and settle counterparty obligations within a year. Analyzing total short-term debt allows for an assessment of the financial stability of Titan Pharmaceuticals (TTNP) during the implementation of eco-friendly implants, where the debt balance is critical for scaling production without the risk of cash flow gaps.

Competitor analysis

Indivior - Company Short-Term Debts|Collegium Pharma (COLL) - Company Current Liabilities|Cronos (CRON) - Company Short-Term Debt|Short-Term Debt Canopy Growth Corp. (CGC)|Company Current Liabilities HITI|ACB: Company Short-Term Loans and Borrowings|Company Short-Term Debts ACHV|SKYE: Current Liabilities|Company Short-Term Debts ANEB (Anebulo)|Company Short-Term Debts InterCure Ltd INCR|NTRB - Company Short-Term Debt|Company Short-Term Loans and Borrowings NSRX (Nasus Pharma Ltd)|igcinc.us (IGC) - Company Short-Term Debt|Company Current Liabilities MIRA Pharmaceuticals, Inc.|Company Current Liabilities FLGC|IMCC (IMC) - Amount of Current Liabilities|Company Short-Term Debts ADIL|Short-Term Debt Volume artelobio.com|Ensysce Biosciences, Inc. - Company Current Liabilities|Amount of Current Liabilities GNLN (Greenlane Holdings, Inc.)|InMed Pharma - Company Short-Term Debts|AKAN - Company Short-Term Debts|Enveric Biosciences (ENVB) - Company Short-Term Debt|Company Short-Term Indebtedness BGXX|Company Current Liabilities HPCO